Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06488911 · ClinicalTrials.gov registry record · Phase 3
To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate
A Phase 3 study, sponsored by Intercept Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
NCT06488911 is a Phase 3 study that was terminated before completion, run by Intercept Pharmaceuticals. The registered enrollment target is 62 participants.
The verdict
NCT06488911, a Phase 3 study, was terminated before completion, sponsored by Intercept Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
Study Summary
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of the Fixed-Dose Combination (FDC) of Obeticholic Acid (OCA) and Bezafibrate (BZF) tablet in Subjects with Primary Biliary Cholangitis (PBC).
Interventions
- DRUG FDC tablet (OCA 5 mg + BZF 400 mg SR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2025-10-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06488911
The ClinicalTrials.gov registry entry for NCT06488911 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intercept Pharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FDC tablet (OCA 5 mg + BZF 400 mg SR) is the first listed.
NCT06488911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06488911 about?
NCT06488911 is a clinical study titled "To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate". An Open Label Long-Term Study to Evaluate the Safety and Tolerability of the Fixed-Dose Combination (FDC) of Obeticholic Acid (OCA) and Bezafibrate (BZF) tablet in Subjects with Primary Biliary Cholangitis (PBC).
What is the current status of trial NCT06488911?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2024-07-01. Estimated completion is 2025-10-21.
What interventions are being tested in trial NCT06488911?
The interventions under investigation include: FDC tablet (OCA 5 mg + BZF 400 mg SR) (DRUG).
Who is sponsoring clinical trial NCT06488911?
This trial is sponsored by Intercept Pharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.